Australia Biologics Market Size, Share, and Trends: Forecast and Growth Analysis Report (2026-2035)

Key Market Trends and Insights

• Based on the source, the microbial segment held over 50% share during the historical period.
• By product, the monoclonal antibodies segment accounted for approximately 65% in the historical period.
• The oncology-based indication segment accounted for around 28% during the historical period.

Market Size and Forecast

• Market Size (2025): AUD 9.96 billion
• Projected Market Size (2035): AUD 17.34 billion
• CAGR (2026-2035): 5.70% 

Australia Biologics Market Overview

Biologics represent a transformative segment in modern medicine, leveraging complex biological processes to develop therapies for chronic, immunological, and life-threatening diseases. Their targeted mechanisms and high efficacy are reshaping treatment approaches across multiple therapeutic areas. The market is witnessing significant expansion, driven by rising demand for advanced therapies, increasing investment in research and development, and growing healthcare infrastructure. The market is poised to grow at a CAGR of 5.70% during the forecast period of 2026-2035, reflecting enhanced adoption of biologics and supportive regulatory frameworks that facilitate innovation and patient access to cutting-edge treatments.

Australia Biologics Market Growth Driver

Rising Cardiovascular Disease Prevalence to Drive Growth

The increasing prevalence of cardiovascular diseases (CVD) in Australia is a significant growth driver for the biologics market. According to the Heart Foundation, 1 in 6 Australians, over 4.5 million people, self-report living with CVD, accounting for nearly 18% of the total population. CVD remains a leading cause of mortality, responsible for around 24% of all deaths. This persistent disease burden is expected to propel the adoption of biologic therapies, supporting sustained market growth.

Australia Biologics Market Trends

Some of the trends in the market include the growing expansion of biosimilars and the increasing rate of biosimilar approvals.

Expansion of Biosimilars Likely to Boost the Market Value

The growing adoption of biosimilars is shaping the market, enhancing patient access to high-quality therapies. For instance, in July 2025, Biocon Biologics launched Nepexto®, a biosimilar to Enbrel®, in Australia. By offering cost-effective alternatives for autoimmune disease treatment, the market is witnessing increased therapeutic availability and competition. This shift toward biosimilars is expected to support sustained growth in the market during the forecast period, driven by rising demand for accessible and effective biologic therapies.

Rising Biosimilar Approvals to Enhance Australia Biologics Market Value

The market is witnessing a strong trend in the approval and adoption of biosimilars, offering cost-effective alternatives for various therapeutic areas. The Therapeutic Goods Administration (TGA) approved multiple biosimilars in early 2025, including Uteknix (ustekinumab), Stoboclo and Osenvelt (denosumab), Tyruko (natalizumab), and Eydenzel (aflibercept). These approvals are expanding patient access to high-quality biologic therapies across autoimmune, oncology, and ophthalmology indications. This increasing acceptance and integration of biosimilars is expected to drive sustained growth and value in the market during the forecast period.

Australia Biologics Market Share

Oncology Segment to Lead the Market by Indication

The market includes various indications such as oncology, immunological disorders, infectious diseases, cardiovascular disorders, hematological disorders, and others. According to the Australian Institute of Health and Welfare, the incidence of cancer in Australia rose from approximately 88,000 cases in 2000 to an estimated 169,000 cases in 2024. Among all indications, the oncology segment is expected to lead the market during the forecast period, driven by increasing patient demand, an aging population, and wider adoption of advanced biologic therapies.

Leading Players in the Australia Biologics Market

The key features of the market report comprise clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Pfizer Inc.

Pfizer Inc., a leading global biopharmaceutical company, develops innovative biologic medicines derived from natural systems, including human, animal, and microbial sources. Its biologics portfolio targets oncology, immunology, neurology, diabetes, and inherited conditions, offering highly effective and precise therapies. Pfizer is also advancing biosimilars, designed to mirror existing licensed biologics, expanding patient access and supporting the growth of the market through clinical development and regulatory-compliant production.

F. Hoffmann La Roche

F. Hoffmann La Roche is a global biopharmaceutical leader specializing in biologics for oncology, chronic inflammatory, and anti-immune conditions. The company offers a comprehensive portfolio, including monoclonal antibodies, recombinant proteins, affinity columns, proteases, and analytical tools like Cedex Analyzers and MycoTOOL kits. Roche supports biopharmaceutical manufacturing and quality control, enabling precise drug development and production, thereby contributing to the growth of the biologics market through advanced biologics solutions and regulatory-compliant processes.

Amgen Inc.

Amgen Inc. is a leading biopharmaceutical company leveraging advanced biotechnology to develop innovative therapies for serious diseases. It offers biologics and high-quality biosimilars, focusing on clinical trial optimization, DNA-encoded libraries, and generative biology. Through robust research, manufacturing capabilities, and scientific initiatives, Amgen actively contributes to the market, enhancing patient access and supporting the development and supply of targeted, effective biologic treatments.

Eli Lilly and Company

Eli Lilly and Company is a leading global pharmaceutical firm specializing in innovative biologics for serious conditions, including cancer, Alzheimer’s, and chronic inflammatory diseases. The company emphasizes high-quality manufacturing, clinical trials, and patient support programs, strengthening its presence in the market and promoting access to advanced, targeted biologic therapies across multiple therapeutic areas.

Other key players in the market include Novartis AG, Sanofi, and Bristol-Myers Squibb Company.

Key Questions Answered in the Australia Biologics Market Report

• What was the Australia biologics market value in 2025?
• What is the Australia biologics market forecast outlook for 2026-2035?
• What are the major factors aiding the Australia biologics market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Australia biologics market trends?
• Which source is expected to dominate the market segment?
• Which product type is projected to lead the market segment?
• Which indication is likely to dominate the market segment?
• Who are the key players involved in the Australia biologics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?